ApoL1

ApoL1

ApoL1 is a circulating human protein that targets and lyses Trypanosomes by forming cation specific ion channels in cell membranes, providing innate immunity to African Sleeping Sickness. Evolutionary pressure from resistant parasites has resulted in the emergence of ApoL1 genetic variants, which provide enhanced immunity but have been linked through genetic and biochemical studies to the increased risk of Chronic Kidney Disease (CKD) in the African American population and populations with recent African ancestry. Ligand has established a drug discovery platform and identified novel inhibitors of the ion channel function of disease linked Apol1 variants. These chemotypes protect cells from deleterious effects following expression of ApoL1 variants and offer the opportunity for optimization into potential therapeutics.